Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Selected
COVID-19
Type of publications
Guidelines (1)
NITAG documentation (354)
SAGE documentation (33)
Scientific publications (4)
Systematic reviews (SYSVAC) (1089)
Regions
Africa (57)
Americas (187)
Eastern Mediterranean (10)
Europe (155)
South-East Asia (10)
Western Pacific (36)
Diseases
COVID-19 (1481)
Chikungunya (9)
Cholera (33)
Cytomegalovirus (1)
Dengue (39)
Diphtheria (79)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (66)
Hepatitis A (63)
Hepatitis B (153)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (66)
HIV / AIDS (10)
Human papillomavirus (HPV) (472)
Influenza (573)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (27)
Measles (128)
Meningococcal disease (145)
Mpox (55)
Mumps (46)
Pertussis (104)
Pneumococcal disease (266)
Poliomyelitis (84)
Q fever (1)
Rabies (28)
Rotavirus (115)
RSV (Respiratory syncytial virus) (47)
Rubella (64)
Salmonella (2)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (59)
Tick-borne encephalitis (12)
Tuberculosis (73)
Typhoid (23)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
Methodological quality (AMSTAR 2)
High (12)
Moderate (7)
Low (111)
Critically low (685)
Not applicable (274)
1481 results found
2022
NITAG-BF recommendation on the introduction of SINOVAC in Burkina Faso
2022
∙
ACIP, Kevin Chatham-Stephens
Pediatric COVID-19 Vaccine Planning for Children 6 Months–4 Years
2022
∙
NACI
Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age
2022
∙
STIKO
Scientific justification of the STIKO for the recommendation of the 2nd COVID-19 booster vaccination with an mRNA vaccine for groups of people who are particularly at risk of health or are exposed
2022
Second booster vaccination against COVID-19
2022
∙
STIKO
STIKO resolution on the 17th update of the COVID-19 vaccination recommendation
2022
∙
NACI
Summary of NACI advice on vaccination with COVID-19 vaccines following myocarditis (with or without pericarditis)
2022
∙
NACI
Updated guidance on a first booster dose of COVID-19 vaccines in Canada
2022
∙
NACI
Updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age
2022
∙
Sara Oliver, ACIP
Updates to the Evidence to Recommendation Framework: Pfizer-BioNTech COVID-19 booster in children aged 5-11 years
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register